Neofect "Ybrain Receives European Patent Approval for Next-Generation Personalized Electronic Medicine... Applied to Depression and Dementia Treatment"

[Asia Economy Reporter Hyunseok Yoo] NeoFect affiliate Ybrain announced on the 21st that it has completed the registration of a European patent for its 'next-generation personalized electronic medicine' technology.

The registered personalized electronic medicine is an ultra-small wearable electronic medicine worn on the head. Unlike existing electrical stimulation devices that use a large-area single electrode, it enhances efficacy and safety through precise local stimulation via divided electrodes, and correction of stimulation location and uniformity. It is characterized by overcoming the limitations of existing large electronic medicines used only in hospitals, allowing patients to use it at home.

Ybrain succeeded in registering this patent by being recognized for its core technology of electronic medicine that automatically recognizes individual head structure and skin condition just by wearing it, achieving optimal efficacy. It adjusts the stimulation location to achieve optimal stimulation transmittance according to individual head structure and reduces uneven stimulation caused by skin condition.

This technology is the result of research and development conducted since 2018 by Ybrain, selected as an executing institution for the 'Pan-Ministerial AI Biorobot Medical Convergence Technology Development Project' jointly promoted by the Ministry of Science and ICT, Ministry of Trade, Industry and Energy, Ministry of Health and Welfare, and Ministry of Food and Drug Safety. Nine domestic research consortia are conducting research and development over five years with a total budget of 42 billion KRW.

Ybrain plans to apply this technology to treat depression, mild dementia, and stroke indications and launch newly designed products tailored to each indication.

A Ybrain official said, "At this important moment when we have successfully completed Phase 3 clinical trials for the indication of depression monotherapy and are entering the medical market in earnest, we have also established protective measures by completing the registration of the European patent for the core technology of personalized electronic medicine." He added, "We are solidifying our position as an industry-leading company by significantly widening the technological gap with latecomers." He further stated, "We expect to secure the AI-based personalized electronic medicine market by accelerating home-based clinical trials through mobile linkage and acquiring real-world usage data."

Ybrain holds the largest intellectual property rights in the domestic electronic medicine field with 93 domestic and international patent applications, 41 domestic patent registrations, and 13 overseas patent registrations.